China’s Biotech Sector Attracts Record Foreign Investment Despite Geopolitical Tensions

14.06.2026 2 Min Read

China’s biotech sector attracts record $12.8B foreign R&D investment in 2025. Global pharma giants expand China operations as innovation matures.

Global pharma giants increase China R&D spending as the domestic innovation ecosystem matures

Foreign pharmaceutical and biotech companies invested a record $12.8 billion in China-based R&D operations in 2025, according to data from the China Chamber of Commerce for Import and Export of Medicines and Health Products. The investment, up 22% from 2024, reflects a growing recognition that China’s biotech ecosystem has reached a level of maturity that makes it indispensable for global drug development pipelines.

AstraZeneca, Roche, Novartis, and Pfizer all expanded their China R&D centers in 2025-2026. AstraZeneca’s $1.5 billion innovation center in Wuxi, which opened in March 2026, is the company’s largest R&D facility outside the UK.

Why China matters for drug development

Three factors drive foreign investment in China’s biotech sector:

Patient population: China’s 1.4 billion people provide access to large, diverse clinical trial populations. Chinese hospitals enroll patients faster than almost any other country.
Talent: China produces more PhD-level life science graduates than any other country. The quality of research has improved dramatically — Chinese institutions now publish more high-impact biomedical papers than US institutions.
Cost: Clinical trials in China cost 40-60% less than in the US or Europe, with comparable data quality.

Domestic innovation rising

Chinese biotech companies are no longer just generic drug manufacturers. Firms like BeiGene, Legend Biotech, and Innovent Biologics have developed innovative therapies that compete globally. BeiGene’s Brukinsa (zanubrutinib) is now the world’s best-selling BTK inhibitor, with global sales exceeding $3 billion in 2025.

The National Medical Products Administration (NMPA) approved 82 innovative drugs in 2025, up from 48 in 2022. The agency has also accelerated its review process, reducing average approval timelines from 18 months to 10 months for priority drugs.

Regulatory and geopolitical risks

The BIOSECURE Act, proposed in the US Congress, could restrict US biotech companies from contracting with Chinese CROs and CDMOs. If enacted, it would force companies like WuXi AppTec and Pharmaron to find alternative revenue sources — potentially accelerating their pivot toward serving non-US markets.

Within China, the healthcare sector faces pricing pressure from the government’s volume-based procurement (VBP) program, which forces dramatic price cuts on drugs included in the national reimbursement list. While VBP has expanded access to essential medicines, it has compressed margins for both domestic and foreign pharmaceutical companies.